EndoClot Plus
Latest round
- Series B
Last raised
- Oct 2018
Total raised
- Undisclosed
Investors
- 1
About EndoClot Plus
EndoClot Plus, Inc.Founded in 2014 and headquartered in Santa Clara, US, EndoClot Plus, Inc. develops medical devices aimed at enhancing bleeding management in the gastrointestinal tract. The company has not undergone significant changes in its business strategy or structure since its inception. The current CEO, Patty Dodson, leads the company, building upon her previous experiences in the medical device industry.EndoClot Plus, Inc. specializes in innovative medical devices designed to address bleeding control in the gastrointestinal tract. Its flagship product, the EndoClot® Polysaccharide Hemostatic System (EndoClot® PHS), employs a proprietary powder that is sprayed directly onto wounds during endoscopic procedures. This technology aims to provide a rapid and effective method for managing gastrointestinal bleeding, a critical need for endoscopists and healthcare professionals in the field. In addition to the EndoClot® PHS, the company also offers the EndoClot® Adhesive and the EndoClot® Submucosal Injection System, which further enhance its portfolio of hemostatic solutions.EndoClot Plus generates revenue through direct sales of its medical devices, particularly the EndoClot® product line, to healthcare institutions and professionals. Transactions typically occur on a B2B basis, where hospitals and clinics purchase these devices to utilize in endoscopic procedures. The pricing structure reflects the value of the innovative technology and its application in critical gastrointestinal interventions. Additionally, the company may engage in partnerships with healthcare providers to facilitate bulk purchasing agreements or distribute products through medical supply wholesalers.EndoClot Plus, Inc. is actively focusing on the development of new products aimed at enhancing its medical device offerings, although specific details and release dates have not been disclosed. The company plans to expand its market presence in China, leveraging its subsidiary established in 2014 to penetrate this growing healthcare market.
Who invested in EndoClot Plus
1 investor across 1 round
See all investors in EndoClot Plus
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Oct 26, 2018
Amount
Undisclosed
Investors
Questions about EndoClot Plus
Who invested in EndoClot Plus?
EndoClot Plus has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EndoClot Plus raised?
EndoClot Plus has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did EndoClot Plus last raise money?
EndoClot Plus's most recent round on record is a Series B, in Oct 2018.
What does EndoClot Plus do?
EndoClot Plus is a biotechnology company.
Where is EndoClot Plus headquartered?
EndoClot Plus is headquartered in Santa Clara, US.
Which VCs invest in companies like EndoClot Plus?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at EndoClot Plus's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like EndoClot Plus? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.